Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
KKR buys stake in Indian firm Gland Pharma for $200 million
8:44 AM MST | December 2, 2013 | Natasha Alperowicz
KKR, a leading global investment firm, says it will acquire a minority stake in Gland Pharma (Hyderabad, India), a leading Indian pure-play generic injectables pharmaceutical products company focusing mainly on the US market. KKR will pay approximately $200 million for the entire stake held by Evolvence India Life Sciences Fund, an existing private equity investor in Gland. The transaction, which will give KKR approximately 35% in Gland, is subject to regulatory approvals and other customary closing conditions. Gland, established in 1978, develops...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee